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which could be attributed to various pharmacological interventions. The critical 
appraisal concluded that the studies were of moderate quality. ConClusions: 
The majority of included RCTs used HF-specific questionnaires, to measure QoL. 
From 2009 onwards, the use of KCCQ increased compared to MLHFQ and KCCQ was 
administered to a comparatively larger study population. Thus, QoL data retrieved 
from studies using KCCQ are considered to be more representative of the real world. 
The inconsistency in reporting of QoL results in RCTs limited comparison of the 
treatment impact on QoL
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objeCtives: In Germany, apheresis is indicated for patients on maximally tolerated 
lipid lowering therapy (max LLT) with uncontrolled low density lipoprotein (LDL) 
levels over 12 months. The current application process restricts patients’ access 
to apheresis although no other treatments are available. Despite its burdensome 
nature and invasiveness, this procedure offers an additional LDL lowering when max 
LLTs are insufficient. This psychodrama market-research aimed to understand the 
patients’ perception of apheresis and how apheresis affects daily living. The core 
concept is to ‘ask without asking’. Methods: Eligible patients had severe hyper-
cholesterolemia, ≥ 1 cardiovascular event, apheresis, and were ≤ 72 years of age. 
The conducted workshops focused on the following topics: 1) disease perception 2) 
perception of apheresis 3) anticipated impact of new therapies on patients’ quality 
of life (QoL). Psychodrama techniques were used to investigate and gain insight into 
the perceptional and emotional world of the patients. A QoL questionnaire (SF-36) 
was applied before (QoL with apheresis) and after the workshop (imagination of 
QoL with a new therapy option). Results: Four workshops took place in October 
2014 in Munich (n= 2), Berlin and Frankfurt. The average age was 63 years (N= 26) 
and patients had broad experience with apheresis. The assessment on the disease 
perception led to feedbacks such as, “It doesn’t hurt and that is bad!”, “My whole 
life changed” or “The fear is in my head!”. Perception of apheresis was ambiguous 
revealing cons (“invasive”, “time-consuming”) and pros (“life-saver”, “effective”). The 
SF-36 evaluation demonstrated an increase in the overall QoL state for the majority 
of patients (n= 20). CONCLUSIONS: Apheresis is seen as burdensome but neces-
sary. Without alternatives, apheresis is considered important by patients, however, 
patients are eager to try new therapies offering more efficacious disease control 
and thereby avoidance of apheresis.
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objeCtives: To quantify preference weights (including willingness to pay = WTP) 
for attributes of a bedside pharmacogenetic test for the CYP2C19*2 allele to permit 
personalization of antiplatelet therapy in patients with acute coronary syndromes 
(ACS). Methods: This internet-based survey tool comprised of: patient demo-
graphics, a decision board and choice sets. Context was provided by way of a deci-
sion board that offered three treatment alternatives for hypothetical ACS patients, 
one of which offered pharmacogenetic testing. Respondents choosing the pharma-
cogenetic option were provided with 8 choice sets; each with two alternatives. Each 
alternative consisted of three attributes, each with three levels. Attributes (levels) 
included: how sample was taken (cheek swab, finger prick or draw blood); turna-
round time for results (1 hour, 3 days, 1 week), and cost expressed as an additional 
annual insurance premium in Canadian dollars (C$)(C$0, C$2, C$10). A full factorial 
design was implemented. A conditional logit regression model was used to analyze 
the responses. The survey was disseminated to randomly selected respondents in 
Ontario (Canada), stratified by age, gender and education. Results: Results are 
generalizable to the Ontario population. Among 328 respondents who completed 
an informed consent for the survey, 219 chose the pharmacogenetic test option 
providing 3472 observations. Exponential coefficients (standard errors) and p val-
ues are as follows: Turnaround; 1 week = 0.089 (0.13) p< 0.0001, 3 days = .243 (0.113) 
p< 0.0001, Sample extraction; finger prick = 1.043 (0.104) p= 0.683, cheekswab = 
1.140 (0.100) = 0.19, cost = 0.63127 (0.032) p< 0.001. WTP in additional annual insur-
ance premiums is C$5.18 for one hour over a 7 day turnaround time and C$3.06 
over a 3 day turnaround. ConClusions: Respondents were 11 times as likely to 
choose a 1 hour turnaround time, and tended to prefer the cheekswab method. 
An incremental WTP was observed for more expedient sample turnaround 
time.
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objeCtives: Heart failure (HF) is an important public health problem that 
depletes a large quantity of health resources. Around 2% of the adult popula-
tion in developed countries suffers from HF. The high prevalence of HF in Spain, 
around 5%, is mostly determined by its population’s progressive ageing. This study 
describes the impact of HF on hospital admissions, length of stay, hospitalization 
confirmed that patients who had a greater improvement in 6MWD (> 40m) at week 
12 of the study had higher mean scores than those with lower improvement (< 40m). 
Furthermore, patients with better functional ability according to WHO classifica-
tion had higher EQ-5D utility scores than those with lower ability. ConClusions: 
Results demonstrate the positive impact of riociguat on patient-reported health 
status among CTEPH patients.
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objeCtives: Hypertension has few subjective symptoms and its treatment must 
be continued long term, as patients may stop visiting the hospital regularly and 
give up on lifestyle improvements. Therefore, the effective and brief coaching-style 
intervention program is essential in community pharmacies. The objective of this 
study was to investigate the effect of intervention by community pharmacists on the 
awareness of continuing treatment among patients with hypertension. Methods: 
This study was designed as a cluster-randomized controlled trial with a 3-month 
intervention period. The subjects comprised adult patients with essential hyper-
tension who had been taking antihypertensive medication for at least 3 months. 
Patients in the intervention group underwent a motivational interview with a phar-
macist lasting around 3 minutes each time they received a prescription, while those 
in the observation group were provided with usual care. Both groups’ patients were 
provided with a home blood pressure monitoring device and pedometer. The study 
outcome was awareness of the continuation of regular hospital visits, healthy diet, 
and appropriate exercise, rated on a 10-point scale from “Extremely important” to 
“Not at all important.” Results: Responses were obtained from 114 patients at 55 
pharmacies (intervention group: 28, observation group: 27). that had enrolled in the 
study A comparison of awareness before and after intervention showed that only 
awareness of regular hospital visits had improved in the observation group (p = 
0.03), whereas in the intervention group, awareness of both regular hospital visits 
(p = 0.04) and appropriate exercise (p = 0.02) showed improvement. ConClusions: 
The findings of this study revealed that intervention by community pharmacists 
may contribute to raising awareness of the need to continue exercise. This result 
implies that pharmacist can improve patients’ ability to chronic disease manage-
ment.
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objeCtives: To measure the quality of life (QoL) of patients 12 months after an 
acute coronary syndrome (ACS) Methods: PGRx-3 are multiusers, multi-countries, 
prospective Real World Datasets assembled to describe disease risk factors, burden 
of disease, disease management, treatment patterns and patient quality of life; they 
are also used for the study of the effectiveness and relative risk of medicines. More 
than 15 disorders have been studied with the PGRx methodology and extensive 
validation studies have been published. Patients are recruited by their physician in 
France, UK, Italy, Germany, Spain and in the US, and interviewed and/or fill a self-
questionnaire. The French PGRx ACS registry has involved 218 investigators since 
October 2013, 90% of them being cardiologists. To date, 3725 patients have been 
included. The self-reported QoL was completed at 12 months, using the EQ-5D and 
SF-12 in a sample of 619 patients who had their follow-up visit between February 
and May 2015. Results: 75% of patients were male, mean age at ACS was 67 years 
[SD= 11], and 71% had a first-lifetime ACS. 12 months after the ACS, the mean score 
of EQ-5D was 0.72 [SD= 0.24], the less favourable ratings were for pain and restriction 
in mobility, considered as “severe” in 10% and 12% of patients, respectively. Using 
the SF-12, 65% patients rated a “good” health, 80 (47%) had limited mobility, and 
70% declared some pain interfering with normal life. ConClusions: 12 months 
after ACS, patients declared a rather good QoL, despite daily limited mobility, pain 
and discomfort.
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objeCtives: Systolic heart failure (HF), is a progressive condition carrying a high 
risk of mortality, hospitalisation and having a significant detrimental impact on 
quality of life (QoL). Current therapies indicated for use in this patient population 
demonstrated beneficial effects on QoL, however the magnitude of effects remain 
debatable. This review was performed to identify QoL instruments (disease spe-
cific and generic) used in systolic heart failure, to estimate the impact of various 
pharmacological interventions. Methods: Publications resulting from Randomised 
controlled trials (RCTs) as well as post-hoc analysis of RCTs from 1996 to October 21, 
2014 were selected using pre-defined inclusion criteria. Critical appraisal of trials 
was performed using the NICE risk of bias tool. Results: A total of 37 publications 
from 33 RCTs met the inclusion criteria. The main HF-specific QoL instruments used 
were the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (8,004 patients) 
in 19 trials and the more recent Kansas City Cardiomyopathy Questionnaire (KCCQ) 
(12,101 patients) in four trials. The generic EQ-5D (VAS) was used in three trials 
whereas SF-36 was used in two trials. Four studies also reported correlations 
between end point changes in morbidity or mortality and change in QoL. Significant 
changes in QoL were found in 9 active and 5 placebo-controlled trials respectively, 
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objeCtives: A structured and comprehensive assessment of disease management 
implementations is not straightforward due to the broadness of the interventions 
and the various evaluation possibilities. The aim of this study was to develop a com-
prehensive framework for outcome measurement of disease management programs 
based on the triple aim framework of the Institute for Healthcare Improvement 
to facilitate future performance assessment using multi-criteria decision analysis 
(MCDA). Methods: Based on literature review and our expertise in performing 
economic evaluations in disease management we identified domains of outcomes 
for each aim of the triple aim framework. For each domain we identified indica-
tors to assess the performance of disease management programs. Results: The 
first aim of the framework, population health improvement, was subdivided into 
the domains health-adjusted life years, mortality, wellbeing, health-related qual-
ity of life (HrQol), complications, symptoms, clinical outcomes, healthy behaviour, 
knowledge, and self-management skills. The second aim, improvement of patient 
experience, was subdivided into patient involvement, patient centeredness, con-
tinuity of care, coordination, communication, information systems, safety and 
access. The third aim of cost reductions distinguished program, medical and non-
medical costs. Potential Indicators of the identified sub-criteria include the ASCOT 
(Adult Social Care Outcomes Toolkit) for measuring wellbeing, smoking rates and 
BMI (Body Mass Index) to measure healthy behaviour, the EuroQol-5D and Short 
Form-36 for measuring physical, mental and social HrQol, different dimensions 
of the PACIC (Patient Assessment of Chronic Illness Care) and CAHPS (Consumer 
Assessment of Healthcare Providers and Systems) for measuring patient experience 
and several measurement tools for measuring friction costs and costs of informal 
care. ConClusions: In designing a structured outcome-based framework for the 
performance evaluation of disease management programs we paved the way for 
future work including a comprehensive evaluation of disease management using 
MCDA. MCDA not only requires measurement of indicators but also weighting of 
their relative importance.
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bACkgRound: Annually in England there are 89,000 strokes. 18% of patients pre-
senting with stroke are in AF at presentation, equating to some 16,000 strokes, of 
which 12,500 are thought to be directly attributable to AF. objeCtives: Reduce the 
number of AF related strokes by optimal anticoagulation according to NICE CG 180. 
Provide education and support to GP practices around identification of patients 
with AF as well as appropriate anticoagulation. Methods: In this analysis, a total 
of 5 GP practices ran the Guidance on Risk Assessment and Stroke Prevention for 
Atrial Fibrillation (GRASP-AF) audit tool to identify patients diagnosed with AF. An 
AF nurse specialist reviewed each patient to ensure that they are on optimal anti-
coagulation based on clinical characteristics and NICE CG 180. Results: A total of 
374 patients have been reviewed with an average age of 77 and an equal proportion 
of males. The majority of patients are diagnosed with permanent AF (54%); have a 
CHA2DS2-VASc score between 3 and 5 (3: 18%, 4: 20%, and 5: 22%) and a HAS-BLED 
score of 2 (48%). The number of patients prescribed aspirin and clopidogrel has 
been reduced from 26% and 6%, to 8% and 3%, respectively. In addition, the num-
ber of patients treated with non-vitamin K antagonist oral anticoagulants (NOACs 
increased from 2% to 19% after treatment review. Patient satisfaction survey results 
revealed that patients are happy with the service and felt at ease discussing treat-
ment options. ConClusions: Overall, 34% of patients received a revised treatment 
regimen based on NICE CG 180. The results indicate that despite not being recom-
mended in NICE CG 180, a high proportion of AF patients are currently managed 
with antiplatelet instead of anticoagulation. In addition, a nurse specialist service 
redesign has the potential to optimise AF anticoagulation services, providing long-
term reductions of AF-related strokes.
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objeCtives: EU5 reimbursement authorities are promoting cost-effective treat-
ment practices against a backdrop of tightening healthcare budgets. However, label 
expansions for novel oral anticoagulants (NOACs) threaten to dramatically increase 
expenditure for the treatment of atrial fibrillation (AF), venous thromboembolism 
(VTE), and acute coronary syndrome (ACS). This study explores the impact of payer 
policies and physician preferences on prescribing for these indications. Methods: 
In December 2014/January 2015, 252 cardiologists across the EU5 were surveyed 
regarding their current and expected prescribing of the NOACs for AF, VTE, and 
ACS. In addition, 15 payers who influence reimbursement at national/regional level 
were interviewed. Results: The impact of cost-containment strategies on NOACs 
uptake varies across the EU5, but is most notable in Spain, where over one-third 
of physicians report that NOACs prescribing is severely restricted by the inspec-
tion visa system. In all countries studied, cost-containment strategies least impact 
AF prescribing, while the greatest impact is on prescribing of rivaroxaban in ACS. 
Overall, surveyed physicians report that, on average, 32-60% of their VTE patients, 
and 48-71% of their AF patients currently receive a NOAC. Uptake is highest in France 
(VTE) and Italy (AF), and lowest in the UK. By 2018, over 60% of physicians in each 
EU5 country anticipate increased use of rivaroxaban and apixaban for both AF and 
VTE. However, expected prescribing of dabigatran etexilate is more varied, and is 
least likely for VTE. Interviewed payers caution that pressure on physicians to pre-
scribe cheaper vitamin K antagonists (VKAs) will likely increase, as will negotiations 
with manufacturers to secure lower NOAC prices are essential. ConClusions: 
Surveyed EU5 cardiologists expect to increase their use of NOACs by 2018. However, 
costs and age adjusted mortality in Spain in 2009-2013. Methods: Statistical 
mining of data stemming from the Spanish Ministry of Health´s heart failure 
related hospital admissions and mortality databases, which are classified by 
International Classification of Disease (ICD) or Diagnosis Related Group (DRG) 
codes: ICD9: 428 (Heart Failure), ICD10: 0907 (Heart failure), DRG: 127 (Heart fail-
ure and Shock) and DRG: 544 (Congestive heart failure and cardiac arrhythmia) 
for the period 2009 to 2013. Results: Hospital admissions due to HF increased 
14.39% from 2009 (89,126) to 2013 (101,953). Yet, the average length of stay in a 
hospital decreased by 7.84% (9.17 vs. 8.45 days). The average cost per admission 
decreased by 9.74%, from € 4,434.50 in 2009 to € 4,002.44 in 2013. The total cost 
increased from € 395 MM to € 408 MM. In regards to age, in 2009, the total cost for 
those under 40 years amounted to € 3.5 MM, € 42 MM for people aged 40-64, € 72 
MM for those aged 65-74, € 165 MM for 75 years to 84 and € 113 MM for 85 years 
or older. A positive trend was observed in the total cost of the eldest patients, 
reaching € 131 MM in 2013. Age-adjusted mortality rate decreased from 19.21 to 
15.90 per 100,000 inhabitants. Total number of deaths also decreased from 17,592 
in 2009 to 16,888 in 2013. ConClusions: The total cost of hospital admissions 
for HF increased in 2013 compared to 2009, while mortality experienced a slight 
decrease.
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objeCtives: To investigate the factors influencing the Severity of illness index of 
the All Patient Refined DRGs (APR-DRG) classification of patients experiencing an 
ischemic stroke. Methods: We conducted a retrospective analysis of ischemic 
stroke patients classified as “APR-DRG 045: CVA & Precerebral Occlusion with 
Infarct” between 2005-2007 admitted to the leading teaching hospital in Belgium. 
Each admission was assigned a primary diagnosis, followed by one or more sec-
ondary diagnoses. Based on an algorithm combining these diagnoses a SOI level 
was assigned to each hospitalization, informing the payment/reimbursement for 
each admission. This classification allows for the relative comparison of patient 
subgroups within each APR-DRG and severity subclass, and was designed to reflect 
the relative resources required for treatment, enabling for the casemix adjustment 
of the payment/reimbursement system. Results: 1,107 stroke admissions were 
recorded during the study period, distributed across four SOI categories: 2% minor, 
44% moderate, 36% major, 18% severe. No relationship was found between the type 
of primary diagnosis and the SOI level. Of the 1,407 secondary diagnoses assigned 
in the dataset, only half (783) were specific to one single SOI category; all others 
were found in 2, 3 or even 4 SOI levels. However a significantly positive relation-
ship was found between the average number of secondary diagnoses assigned per 
patient and the SOI: on average 5.9, 11.3, 19.4 and 25.6 secondary diagnoses were 
allocated for increasing levels of SOI. Secondary diagnoses such as MI, diabetes, 
atrial fibrillation, hypertension, hypercholesterolemia, smoking, atherosclerosis 
were individually not linked to more severe levels of SOI, however the combination 
of these factors did affect a patient’s SOI. ConClusions: Payment/ reimburse-
ment decisions for patients experiencing an ischemic stroke will be based on the 
resources necessary to manage a case mix of secondary diagnoses rather than be 
informed by the severity of the stroke.
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objeCtives: MGEN, a health insurance covering mainly teachers in France, is look-
ing to set up a coronary heart diseases (CHD) prevention program in order to reduce 
CHD mortality, morbidity, and associated costs. However, due to the particular 
demographics of the covered population, the expected benefits of the program, given 
the programs parameters, is difficult to foresee. Yet, an estimation of the program 
effectiveness could help promote the programs importance to decision makers, 
motivate individuals responsible for the program implementation and encourage 
patient enrolment. Thus, the objective of this study was to construct a tool that 
could simulate the effectiveness of CHD prevention based on the demographical 
characteristics of the target population. Methods: We constructed a micro-simula-
tion model that simulated a cohort of individuals participating in a CHD prevention 
program. Individuals’ baseline characteristics were based on age and sex distribu-
tion. CHD risk factors including systolic arterial pressure, body mass index, total 
cholesterol, smocking, diabetes, stroke and CHD prevalences were fitted by age and 
sex for the French population. Effectiveness values for CHD prevention programs 
were based on the COCHRANE review. One-year and ten year CHD mortality were 
estimated from SCORE and 10 years CHD events from FRAMINGHAM. Results: 
Implementing a prevention program in a population of a 100 000 representative of 
the insurance population with a 27% participation rate reduced CHD mortality by 
9 after 1 year. The number needed to treat (NNT) was 2988. Excluding individuals 
with no CHD risk factors reduced NNT to 1571 with a similar mortality reduction. 
Further excluding participants of 44 years or less reduced NNT to 947 and double 
the mortality reduction. ConClusions: The effectiveness and efficiency of a CHD 
prevention program is sensitive to the target population. Simulation tools are use-
ful to decision makers to better specify the target population in order to optimize 
the program’s efficiency.
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